Amgen Withdraws EU Application For Its Infliximab Biosimilar

 
• By Akriti Seth
  
Compass_Strategy
A change in product strategy motivates Amgen to withdraw its application for marketing authorization • Source: Shutterstock

More from Strategy

More from Business